Three-in-one antibody may protect from HIV-like virus

A three-pronged antibody made in the laboratory has been found to protect monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived.

The three-pronged antibody, created by investigators from the National Institutes of Health (NIH) and the Paris-based pharmaceutical company Sanofi, also stopped a greater number of HIV strains from infecting cells in the laboratory more potently than natural, single antibodies.

This new broadly neutralising antibody binds to three different critical sites on HIV.

Plans are underway to conduct early-phase clinical trials of the “tri-specific” antibody in healthy people and in people living with HIV in the hope that it could eventually be used for long-acting HIV prevention and treatment. By binding to three different sites on the virus, the new antibody should be harder for HIV to dodge than natural, single antibodies.

“Combinations of antibodies that each bind to a distinct site on HIV may best overcome the defences of the virus in the effort to achieve effective antibody-based treatment and prevention,” said Dr Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, part of NIH. “The concept of having a single antibody that binds to three unique sites on HIV is certainly an intriguing approach for investigators to pursue.”

The tri-specific antibody reported was created and tested through a collaborative research and development agreement between NIAID and Sanofi under the leadership of Dr John R. Mascola, director of the NIAID Vaccine Research Center (VRC), and Sanofi Chief Scientific Officer and Senior Vice President Dr Gary J. Nabel.

The three HIV-binding segments of the antibody are based on three individual HIV antibodies, each of which powerfully neutralises many strains of the virus. Scientists at NIAID and the IAVI Neutralising Antibody Consortium of The Scripps Research Institute in La Jolla, California, previously isolated these individual antibodies from people living with HIV.

Researchers at the VRC and Sanofi tested dozens of bispecific and tri-specific antibodies in the laboratory to find the best-performing combination. Individual antibodies were combined with tri-specific antibodies using technology proprietary to Sanofi. The most successful formula combines the unique structures of the broadly neutralising HIV antibodies called VRC01, PGDM1400, and 10E8v4.

VRC scientists tested this tri-specific antibody in an experiment involving monkeys and two strains of SHIV. One SHIV strain is sensitive to neutralisation by VRC01 and the tri-specific antibody but resistant to neutralisation by PGDM1400. The other SHIV strain is sensitive to neutralization by PGDM1400 and the tri-specific antibody but resistant to neutralization by VRC01. Scientists from the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston provided these SHIV strains.

The other SHIV strain is sensitive to neutralization by PGDM1400 and the tri-specific antibody but resistant to neutralization by VRC01. Scientists from the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston provided these SHIV strains.

The other SHIV strain is sensitive to neutralisation by PGDM1400 and the tri-specific antibody but resistant to neutralisation by VRC01. 

The VRC researchers gave infusions of VRC01 to eight monkeys, PGDM1400 to another eight monkeys, and the tri-specific antibody to the third group of eight monkeys. Five days later, the scientists exposed all 24 monkeys to both SHIV strains. Five of the eight monkeys that received PGDM1400 and six of the eight monkeys that received VRC01 became infected with SHIV, but none of the monkeys that received the tri-specific antibody became infected.

Five days later, the scientists exposed all 24 monkeys to both SHIV strains. Five of the eight monkeys that received PGDM1400 and six of the eight monkeys that received VRC01 became infected with SHIV, but none of the monkeys that received the tri-specific antibody became infected.

Sanofi is manufacturing the tri-specific antibody for use in a Phase 1 clinical trial that will be conducted by NIAID to test the antibody’s safety and pharmacokinetics in healthy people beginning in late 2018. Discussions also are underway with the NIAID-funded AIDS Clinical Trials Group to conduct a separate Phase 1 clinical trial of the antibody in people living with HIV.

Discussions also are underway with the NIAID-funded AIDS Clinical Trials Group to conduct a separate Phase 1 clinical trial of the antibody in people living with HIV.

The ability of tri-specific antibodies to bind to three independent targets at once could make them a useful prototype for treatments developed not only for HIV but also for other infectious diseases, autoimmune diseases and cancers, according to the study authors.